As this is not an economic evaluation, the study did not assess the comparative cost-effectiveness of PD1/PD-L1 inhibitors for metastatic NSCLC, which could vary significantly by country contexts due to different potential alternative use of financial resources (i.e., opportunity cost). The gene discussed is CD274; the disease is non-small cell lung carcinoma.